Abstract:Background: Pyrogallol, a bioactive compound derived from natural sources, is the focus of this study, aiming to investigate its anti-cancer properties against A549 lung cancer cells and uncover the underlying mechanisms. Purpose: This study seeks to elucidate the therapeutic potential of pyrogallol as a novel anti-cancer agent for NSCLC by targeting aerobic glycolysis and signal transducer and activator of transcription 2 (STAT2) signaling pathway. Background: Pyrogallol, a bioactive compound derived from natural sources, is the focus of this study, aiming to investigate its anti-cancer properties against A549 lung cancer cells and uncover the underlying mechanisms. Materials and methods: A range of pyrogallol doses was administered to A549 cells, followed by a comprehensive analysis utilizing bioinformatic tools like Gene Expression Omnibus (GEO), GEO2R, WebGestalt, and the Search Tool for Interactions of Chemicals database. Assessments of cytotoxicity were conducted using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and trypan blue assays post-treatment of A549 cells with pyrogallol. Cell cycle progression and cell death were evaluated via flow cytometry using Annexin V-fluorescein isothiocyanates/propidium iodide double staining. Network analysis helped identify pertinent signaling pathways, while RT-PCR validated mRNA expression changes in A549 cells. Auto dock docking studies were employed to gauge the binding affinity of pyrogallol with targets associated with the STAT2-mediated pathway. Results: Pyrogallol notably impeded the progression of A549 cells by prompting cell cycle arrest in the G0/G1 phase and fostering apoptosis. Network analysis highlighted its role in regulating metabolism, apoptosis, and STAT2 targets linked to lung tumorigenesis. RT-PCR validation affirmed the downregulation of genes associated with cell cycle and apoptosis targets. Furthermore, docking studies indicated a robust binding affinity between pyrogallol and the signaling targets within the STAT2 pathway. Pyrogallol displays the potential to halt the growth of lung cancer cells, indicating its promise as a viable treatment for this condition. Conclusion: These discoveries emphasize the need for additional research and clinical studies to fully harness its therapeutic benefits for lung cancer treatment.

1-Pyrroline-5-carboxylate inhibit T cell glycolysis in prostate cancer microenvironment by SHP1/PKM2/LDHB axis

1-Pyrroline-5-carboxylate released by prostate Cancer cell inhibit T cell proliferation and function by targeting SHP1/cytochrome c oxidoreductase/ROS Axis

Tadalafil increases the antitumor activity of 5-FU through inhibiting PRMT5-mediated glycolysis and cell proliferation in colorectal cancer

Tumor ABCC4-mediated release of PGE2 induces CD8+ T cell dysfunction and impairs PD-1 blockade in prostate cancer

Pyrroline-5-carboxylate Reductase 1 Promotes Proliferation and Inhibits Apoptosis in Non-Small Cell Lung Cancer

CPT1A mediates the succinylation of SP5 which activates transcription of PDPK1 to promote the viability and glycolysis of prostate cancer cells

Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy

Poly(ADP-ribose) Glycohydrolase Silencing Down-Regulates TCTP and Cofilin-1 Associated with Metastasis in Benzo(a)pyrene Carcinogenesis.

Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy

Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity to hinder tumor growth and metastasis in prostate cancer through EGFR/JAK1/STAT3 pathway to inhibit PD-1/PD-L1 checkpoint signaling

The Effect and Mechanism of Astragalus Polysaccharides on T Cells and Macrophages in Inhibiting Prostate Cancer

Dual Action on Promoter Demethylation and Chromatin by an Isothiocyanate Restored Gstp1 Silenced in Prostate Cancer

Targeting prostate tumor low–molecular weight tyrosine phosphatase for oxidation-sensitizing therapy

Pyrogallol promotes growth arrest by activating the p53-mediated up-regulation of p21 and p62/SQSTM1-dependent degradation of β-catenin in nonsmall cell lung cancer cells

Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer

Traditional Chinese Medicine CFF‐1 induced cell growth inhibition, autophagy, and apoptosis via inhibiting EGFR‐related pathways in prostate cancer

Pyrogallol Suppresses the Tumor Progression via Modulating Aerobic Glycolysis and STAT2 Signaling Pathway in Non-small Cell Lung Carcinoma

p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP

Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells

CIP2A induces PKM2 tetramer formation and oxidative phosphorylation in non-small cell lung cancer

PCC0208057 as a small molecule inhibitor of TRPC6 in the treatment of prostate cancer